Home
VNDA
VNDA News

Latest Vanda Pharmaceuticals Inc. (VNDA) News on August 3, 2025

3 Promising Penny Stocks With Market Caps Under $400M

Simply Wall St.

a month ago

3 Promising Penny Stocks With Market Caps Under $400M

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

PR Newswire

2 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

PR Newswire

2 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 05/21/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/16/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/15/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/14/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/09/2025

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Vanda Pharmaceuticals Inc Earnings Call

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/08/2025

Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...

GuruFocus.com

3 months ago

Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Vanda: Q1 Earnings Snapshot

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

PR Newswire

3 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/07/2025

3 Penny Stocks Under $300M Market Cap To Consider

Simply Wall St.

3 months ago

3 Penny Stocks Under $300M Market Cap To Consider

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/06/2025

MT Newswires

3 months ago

Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

PR Newswire

3 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/05/2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

PR Newswire

3 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/02/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 05/01/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/30/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/29/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/28/2025

FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

Pharma Voice

3 months ago

FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/25/2025

Halozyme sues Merck; FDA blames cuts for Vanda delay

BioPharma Dive

3 months ago

Halozyme sues Merck; FDA blames cuts for Vanda delay

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/24/2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

PR Newswire

3 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/23/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/22/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 04/21/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/18/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/17/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/16/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/15/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/14/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/11/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/10/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/09/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/08/2025

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

PR Newswire

4 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/07/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/04/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/03/2025

High Growth Tech Stocks In US With Promising Potential

Simply Wall St.

4 months ago

High Growth Tech Stocks In US With Promising Potential

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/02/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 04/01/2025

MT Newswires

4 months ago

Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

PR Newswire

4 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/31/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/28/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/27/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/26/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/25/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/24/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/21/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/20/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/19/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/18/2025

MT Newswires

5 months ago

Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/17/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/14/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/13/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/12/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/11/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/10/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/07/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/06/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/05/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 03/03/2025

US High Growth Tech Stocks With Strong Potential

Simply Wall St.

5 months ago

US High Growth Tech Stocks With Strong Potential

February 2025 Penny Stocks To Keep An Eye On

Simply Wall St.

5 months ago

February 2025 Penny Stocks To Keep An Eye On

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

PR Newswire

5 months ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Vanda Pharmaceuticals Inc Earnings Call

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

GuruFocus.com

6 months ago

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

6 months ago

Vanda: Q4 Earnings Snapshot

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

6 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

PR Newswire

6 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Pharmaceutical Technology

6 months ago

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

MT Newswires

6 months ago

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

GlobeNewswire

6 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioPharma Dive

6 months ago

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

US Exchange Penny Stocks To Watch In January 2025

Simply Wall St.

6 months ago

US Exchange Penny Stocks To Watch In January 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

PR Newswire

6 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

Benzinga

7 months ago

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

MT Newswires

7 months ago

Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

PR Newswire

7 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Zacks

7 months ago

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Zacks

7 months ago

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks

7 months ago

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

MT Newswires

7 months ago

Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

PR Newswire

7 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

7 months ago

Exploring Three High Growth Tech Stocks In The United States

US Penny Stocks To Watch In December 2024

Simply Wall St.

8 months ago

US Penny Stocks To Watch In December 2024

New Strong Buy Stocks for November 14th

Zacks

9 months ago

New Strong Buy Stocks for November 14th

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

PR Newswire

9 months ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Share on Social Networks: